Ponatinib
| Generic name | Ponatinib |
| Pronunciation | poe-NA-ti-nib |
| Brand name(s), other common name(s) | Iclusig® |
| Drug type | Tyrosine kinase inhibitor |
| How the drug is given | By mouth |
Iclusig is FDA approved to treat adult patients who have chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy, or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Side effects needing medical attention:
Hypertension; rash; abdominal pain; fatigue; dizziness; headache; cough; dry skin; constipation; joint pain; nausea; diarrhea; vomiting; fever; low platelets; low red blood cells; low neutrophils; low level of lymphocytes; low white blood cell count; cardiac failure; pneumonia; respiratory tract infection, urinary tract infection; peripheral neuropathy; back pain; muscle spasms; bone pain; fatigue.
For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.
